<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-24-11-2025-shutterstock_1958741605-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-24-11-2025-shutterstock_1958741605-430x241.jpg"/>
                                    
                                    <figcaption>AstraZeneca’s US operations include 19 sites and more than 25,000 staff. Credit: Grand Warszawski/Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>AstraZeneca has announced a $2bn investment plan to expand its biomanufacturing presence in the US state of Maryland, aiming to support 2,600 jobs at its Frederick and Gaithersburg sites.</p>



<p>The investment covers both expansion of the Frederick biologics manufacturing facility and a new plant construction in Gaithersburg, targeting operational readiness by 2029.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: AstraZeneca Plc's AZD-8205 </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: AstraZeneca Plc's MEDI-7352 </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The Frederick site, which produces biologics used in autoimmune, cancer, rare disease and respiratory treatments, will almost double its commercial manufacturing capacity through the planned expansion.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>It will generate 900 construction roles and 200 skilled jobs.</p>



<p>AstraZeneca will also build a new manufacturing facility in Gaithersburg to develop and supply new molecules for use in clinical trials.</p>



<p>This site will back 1,000 construction-related jobs, create 100 new jobs and retain 400 existing roles.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Both facilities will utilise data analytics, advanced AI and automation, and will be designed to comply with high environmental standards.</p>



<p>AstraZeneca CEO Pascal Soriot stated: “Today marks a landmark moment for Maryland and American patients. As the state’s largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland – supporting 2,600 jobs, catalysing economic growth and bringing our extensive rare disease portfolio onshore for the first time.</p><div id="slot-two"></div>



<p>“This investment strengthens the resilience of the US medicines supply chain and accelerates access to transformative therapies for patients across America and around the world.”</p>



<p>The latest development is part of AstraZeneca’s $50bn investment initiative that was announced in July 2025.</p>



<p>It follows the expansion of the company’s existing manufacturing site in Coppell, Texas, the opening of a new cell therapy manufacturing plant in Rockville, Maryland, and the establishment of a new drug substance production facility in Virginia.</p>



<p>AstraZeneca’s US operations now cover 19 research and development, commercial and manufacturing sites, employ more than 25,000 staff and support 100,000 jobs. In 2025, it created $20bn of value for the US economy.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
                 <p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
Nominate Now

             </div>

<p>AstraZeneca has announced a $2bn investment to expand its biomanufacturing in Maryland, US. The plan includes expanding the Frederick biologics manufacturing facility and constructing a new plant in Gaithersburg, supporting 2,600 jobs. The Frederick site will nearly double its capacity, while the Gaithersburg facility will develop new molecules for clinical trials. Both sites will use advanced AI and automation. This investment is part of AstraZeneca's $50bn initiative announced in 2025, aimed at strengthening the US medicines supply chain and accelerating access to therapies.</p>

AstraZeneca to expand biomanufacturing in Maryland, US